BamSEC and AlphaSense Join Forces
Learn More

Bellerophon Therapeutics Inc

Formerly OTC: BLPH
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 5 pages Bellerophon Therapeutics, Inc. Series a Non-Convertible Preferred Stock Subscription and Investment Representation Agreement
12/34/56
EX-10.3
from 10-Q 7 pages ​ August 3, 2023 Parag S. Shah Re: Separation Agreement ​ Dear Parag: ​ the Purpose of This Letter Agreement (This “Agreement”) Is to Set Forth the Terms of Your Transition and Separation From Bellerophon Therapeutics, Inc. (The “Company”)
12/34/56
EX-10.2
from 10-Q 7 pages ​ August 3, 2023 Peter P. Fernandes Re: Separation Agreement ​ Dear Peter: ​ the Purpose of This Letter Agreement (This “Agreement”) Is to Set Forth the Terms of Your Transition and Separation From Bellerophon Therapeutics, Inc. (The “Company”)
12/34/56
EX-10.1
from 10-Q 7 pages ​ July 13, 2023 Martin P. Dekker Re: Separation Agreement ​ Dear Martin: ​ the Purpose of This Letter Agreement (This “Agreement”) Is to Set Forth the Terms of Your Transition and Separation From Bellerophon Therapeutics, Inc. (The “Company”)
12/34/56
EX-10.1
from 8-K 10 pages Appendix a Bellerophon Therapeutics LLC Amended and Restated 2015 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 36 pages Technology License Agreement
12/34/56
EX-10.1
from 8-K 8 pages May 4, 2023 Nick Laccona ​ Re: Separation Agreement Dear Nick: The Purpose of This Letter Agreement (This “Agreement”) Is to Set Forth the Terms of Your Separation From Bellerophon Therapeutics (The “Company”). Payment of the Separation Benefits Described Below Is Contingent on Your Agreement to and Compliance With the Terms of This Agreement
12/34/56
EX-10.1
from 8-K 12 pages ​ Subscription Agreement
12/34/56
EX-10.1
from 8-K 6 pages Vesting Schedule
12/34/56
EX-10.1
from 8-K 39 pages Open Market Sale Agreementsm
12/34/56
EX-10.1
from 8-K 6 pages May 18, 2020 Personal and Confidential Angel Pond Capital LLC 950 Third Avenue, 25th Floor New York, Ny 10022 This Agreement (The “Agreement”) Is Entered Into as of May 18, 2020 Between Bellerophon Therapeutics, Inc. (The “Company”) and Angel Pond Capital LLC (“Advisor”). the Company and Advisor Shall Collectively Be Referred to as the “Parties” and Each a “Party.”
12/34/56
EX-10.1
from 8-K 33 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 6 pages Material contract
12/34/56
EX-10.2
from 8-K ~5 pages Fourth Amendment to Exclusive Cross-License, Technology Transfer and Regulatory Matters Agreement
12/34/56
EX-10.1
from 8-K 1 page Third Amendment to Drug Clinical Supply Agreement
12/34/56
EX-10.3
from 8-K 13 pages Warrant to Purchase Shares of Common Stock of Bellerophon Therapeutics, Inc
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 31 pages Bellerophon Therapeutics, Inc. Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 6 pages May 9, 2017 Strictly Confidential Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 A.COMPENSATION; Reimbursement. at the Closing of Each Offering (Each, a “Closing”), the Company Shall Compensate Wainwright as Follows: 1.cash Fee. the Company Shall Pay to Wainwright a Cash Fee, or as to an Underwritten Offering an Underwriter Discount, Equal to 7.0% of the Aggregate Gross Proceeds Raised in Each Offering
12/34/56
EX-10.1
from 8-K 33 pages Securities Purchase Agreement
12/34/56